Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Agalsidase beta 3 endocrinologydiseasesdrugs
Fabry disease 5 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Agalsidase beta 3316 to have higher rates of composite endpoints compared to those receiving agalsidase beta.Conclusions Agalsidase beta is associated to a significantly lower incidence of renal, cardiovascular and cerebrovascular events
Agalsidase beta 35297 regard, the results are not surprising. Rather, they lend further support to results from small RCTs. Agalsidase beta was superior to placebo in the only available RCT (n = 82) with primary end-point of severe clinical
Agalsidase beta 39030 identified the low sample size of RCTs as a real challenge for the analysis of rare diseases.Conclusions Agalsidase beta is associated to a significantly lower incidence of renal, cardiovascular and cerebrovascular events
Select Disease Character Offset Disease Term Instance
Fabry disease 55 Title: PLoS ONEEnzyme replacement therapy for Anderson- Fabry disease : A complementary overview of a Cochrane publication through a linear regression and a pooled analysis
Fabry disease 264 analysis of proportions from cohort studiesAlternative Title: Enzyme replacement therapy for Anderson- Fabry disease : A complementary overviewRegina El DibHuda GomaaAlberto OrtizJuan PoliteiAnil KapoorFellype Barreto
Fabry disease 1061 STATESPublication date (epub): 3/2017Publication date (collection): /2017AbstractBackgroundAnderson- Fabry disease (AFD) is an X-linked recessive inborn error of glycosphingolipid metabolism caused by a deficiency of
Fabry disease 3775 AvailabilityAll relevant data are within the paper and its Supporting Information files.IntroductionAnderson- Fabry disease (AFD) is an X-linked recessive inborn error of glycosphingolipid metabolism caused by deficiency of
Fabry disease 35172 benefits of using ERT, an observation that should be taken into account in health policy debates regarding Fabry disease . In this regard, the results are not surprising. Rather, they lend further support to results from small

You must be authorized to submit a review.